HaematologicaPub Date : 2025-01-01DOI: 10.3324/haematol.2024.286346
Mark R Litzow
{"title":"The real world of acute lymphoblastic leukemia.","authors":"Mark R Litzow","doi":"10.3324/haematol.2024.286346","DOIUrl":"10.3324/haematol.2024.286346","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"20-21"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HaematologicaPub Date : 2025-01-01DOI: 10.3324/haematol.2023.284448
Pierre Stephan, Jimmy Perrot, Allison Voisin, Maud Barbery, Thibault Andrieu, Maxime Grimont, Julie Caramel, Mathilde Bardou, Garance Tondeur, Edoardo Missiaglia, Philippe Gaulard, François Lemmonier, Laurence De Leval, Emmanuel Bachy, Pierre Sujobert, Laurent Genestier, Alexandra Traverse-Glehen, Yenkel Grinberg-Bleyer
{"title":"Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets.","authors":"Pierre Stephan, Jimmy Perrot, Allison Voisin, Maud Barbery, Thibault Andrieu, Maxime Grimont, Julie Caramel, Mathilde Bardou, Garance Tondeur, Edoardo Missiaglia, Philippe Gaulard, François Lemmonier, Laurence De Leval, Emmanuel Bachy, Pierre Sujobert, Laurent Genestier, Alexandra Traverse-Glehen, Yenkel Grinberg-Bleyer","doi":"10.3324/haematol.2023.284448","DOIUrl":"10.3324/haematol.2023.284448","url":null,"abstract":"<p><p>Whereas immunotherapies have revolutionized the treatment of different solid and hematologic cancers, their efficacy in nodal peripheral T-cell lymphomas (PTCL) is limited, due to a lack of understanding of the immune response they trigger. To fully characterize the immune tumor microenvironment (TME) of PTCL, we performed spectral flow cytometry analyses on 11 angioimmunoblastic T-cell lymphomas (AITL), 7 PTCL, not otherwise specified (PTCL, NOS) lymph node samples, and 10 non-tumoral control samples. The PTCL TME contained a larger proportion of regulatory T cells and exhausted CD8+ T cells, with enriched expression of druggable immune checkpoints. Interestingly, CD39 expression was up-regulated at the surface of most immune cells, and a multi-immunofluorescence analysis on a retrospective cohort of 43 AITL patients demonstrated a significant association between high CD39 expression by T cells and poor patient prognosis. Together, our study unravels the complex TME of nodal PTCL, identifies targetable immune checkpoints, and highlights CD39 as a novel prognostic factor.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"129-141"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141175033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HaematologicaPub Date : 2025-01-01DOI: 10.3324/haematol.2024.285219
Ángel Serna, Víctor Navarro, Gloria Iacoboni, Laia López, Juan-Manuel Sancho, Eva González-Barca, Alberto López-García, Raúl Córdoba, Adolfo Sáez, Ana Jiménez-Ubieto, Ainara Ferrero, Tomás García, Ángela Sánchez, Cristina García, Marc Bosch, Alba Cabirta, Moraima Jiménez, Ana Marín-Niebla, Francesc Bosch, Pau Abrisqueta
{"title":"Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes.","authors":"Ángel Serna, Víctor Navarro, Gloria Iacoboni, Laia López, Juan-Manuel Sancho, Eva González-Barca, Alberto López-García, Raúl Córdoba, Adolfo Sáez, Ana Jiménez-Ubieto, Ainara Ferrero, Tomás García, Ángela Sánchez, Cristina García, Marc Bosch, Alba Cabirta, Moraima Jiménez, Ana Marín-Niebla, Francesc Bosch, Pau Abrisqueta","doi":"10.3324/haematol.2024.285219","DOIUrl":"10.3324/haematol.2024.285219","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"173-178"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HaematologicaPub Date : 2025-01-01DOI: 10.3324/haematol.2024.286063
Yishai Ofran, Jacob M Rowe
{"title":"Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia - the CONS.","authors":"Yishai Ofran, Jacob M Rowe","doi":"10.3324/haematol.2024.286063","DOIUrl":"10.3324/haematol.2024.286063","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"110 1","pages":"7-10"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HaematologicaPub Date : 2025-01-01DOI: 10.3324/haematol.2024.285185
Tamer Othman, Paul Frankel, Pamela Allen, Leslie L Popplewell, Geoffrey Shouse, Tanya Siddiqi, Alexey V Danilov, Nora Ruel, Shari Daniels, Lacolle Peters, Stella Khoo, Steven T Rosen, Elad Sharon, Miguel Villalona-Calero, Christopher Ruel, Joseph Tuscano, Alex F Herrera
{"title":"Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma.","authors":"Tamer Othman, Paul Frankel, Pamela Allen, Leslie L Popplewell, Geoffrey Shouse, Tanya Siddiqi, Alexey V Danilov, Nora Ruel, Shari Daniels, Lacolle Peters, Stella Khoo, Steven T Rosen, Elad Sharon, Miguel Villalona-Calero, Christopher Ruel, Joseph Tuscano, Alex F Herrera","doi":"10.3324/haematol.2024.285185","DOIUrl":"10.3324/haematol.2024.285185","url":null,"abstract":"<p><p>Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) transformed from indolent B-cell lymphomas, including Richter transformation, have a poor prognosis. PD-1/PD-L1 antibodies produce modest objective and complete response rates in B-cell non-Hodgkin lymphoma as monotherapy but may synergize with immunogenic chemotherapies such as gemcitabine and oxaliplatin (GemOx). Thus, we evaluated the safety and efficacy of atezolizumab plus rituximab and GemOx (R-GemOx+Atezo) in R/R transformed DLBCL, including Richter transformation. We conducted a phase I trial including patients with transformed DLBCL after ≥1 prior therapy. Patients received up to four cycles of R-GemOx+Atezo. Patients in complete remission could then proceed to R-Atezo maintenance until progression. A safety lead-in with evaluation of dose-limiting toxicity was performed to confirm the recommended phase II dose; subsequently the treatment was administered to two expansion cohorts: one with transformed follicular lymphoma (FL) and the other with non-FL transformed DLBCL, including Richter transformation. Twenty-seven patients were enrolled. One of the six patients in the safety lead-in had a dose-limiting toxicity attributed to atezolizumab, a grade 4 Stevens-Johnson syndrome. The most common grade ≥3 events were neutropenia (18.5%), lymphopenia (18.5%), and thrombocytopenia (14.8%). The overall and complete response rates were 59% and 33%, respectively. The overall and complete response rates in transformed FL were 79% and 43%, respectively, and 38% and 23% in transformed non-FL, respectively. The median progression-free survival and overall survival of the total population were 4.2 and 7.7 months, respectively. R-GemOx+Atezo was well tolerated and demonstrated promising preliminary efficacy in patients with relapsed/refractory transformed DLBCL.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"142-152"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HaematologicaPub Date : 2025-01-01DOI: 10.3324/haematol.2024.285547
Lili Feng, Haohai Zhang, Changchuin Mao, Paola De Andrade Mello, Dina Stroopinsky, Eva Csizmadia, Jialin Zhou, David Avigan, Jinming Yu, Wenda Gao, Simon C Robson
{"title":"Cd39 and P2rx7-Wnt signaling enhance blast pathogenicity in an experimental model of acute myeloid leukemia.","authors":"Lili Feng, Haohai Zhang, Changchuin Mao, Paola De Andrade Mello, Dina Stroopinsky, Eva Csizmadia, Jialin Zhou, David Avigan, Jinming Yu, Wenda Gao, Simon C Robson","doi":"10.3324/haematol.2024.285547","DOIUrl":"10.3324/haematol.2024.285547","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"212-217"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HaematologicaPub Date : 2025-01-01DOI: 10.3324/haematol.2024.285045
Kadère Konté, Dorine W Swinkels, Ilona Kleine Budde, Erfan Nur, Bart J Biemond
{"title":"Safety and efficacy of human apotransferrin infusion in patients with β-thalassemia intermedia: the AIM study.","authors":"Kadère Konté, Dorine W Swinkels, Ilona Kleine Budde, Erfan Nur, Bart J Biemond","doi":"10.3324/haematol.2024.285045","DOIUrl":"10.3324/haematol.2024.285045","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"183-186"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142106896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}